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Abstract
Tianeptine is an atypical antidepressant with a unique mechanism of action and recently it has been also reported that its major
metabolite, compound MC5, possesses pharmacological activity similar to that of the parent drug. The current study aims to
investigate the pharmacokinetics (PK) of both tianeptine and MC5 after intravenous or intraperitoneal administration of the
parent drug as well as the metabolic ratio of MC5 in rats. To achieve these goals an LC-MS/MS method using the small sample
volume for the quantitation of tianeptine and its active metabolite MC5 in rat plasma and liver perfusate has been developed and
validated. Following an intravenous administration of tianeptine pharmacokinetic parameters were calculated by non-
compartmental analysis. The average tianeptine volume of distribution at steady state was 2.03 L/kg and the systemic clearance
equaled 1.84 L/h/kg. The mean elimination half-lives of tianeptine and MC5 metabolite were 1.16 and 7.53 h, respectively. The
hepatic clearance of tianeptine determined in the isolated rat liver perfusion studies was similar to the perfusate flow rate despite
the low metabolic ratio of MC5. Mass spectrometric analysis of rat bile indicated that tianeptine and MC5 metabolite are
eliminated with bile as glucuronide and glutamine conjugates. Bioavailability of tianeptine after its intraperitoneal administration
was 69%. The PK model with a metabolite compartment developed in this study for both tianeptine and MC5 metabolite after
two routes of administration may facilitate tianeptine dosage selection for the prospective pharmacological experiments.
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Introduction
The challenge of treatment-resistant depression is one of the
most significant in contemporary psychiatric therapy. It has
been reported that only one-third of major depressive patients
achieve remission after 3 months of monotherapy with anti-
depressants. The most common approaches for these patients
include switching to another antidepressant of the same or
different group or combining antidepressants with, e.g.,
atypical antipsychotics (Tobe and Rybakowski 2013).
Tianeptine is an antidepressant in clinical use that has drawn
much attention because of its unique mechanism of action. In
contrast to tricyclic antidepressants (TCAs) and selective se-
rotonin reuptake inhibitors (SSRI), tianeptine enhances the
synaptic uptake of serotonin with minimal effects on that of
norepinephrine and dopamine; nevertheless, its efficacy
against depressive episodes is comparable with that of TCAs
and fluoxetine (Uzbay 2008; Woo et al. 2013). It shows a
faster onset of therapeutic effects against some depressive
symptoms (cognitive and anxiety symptoms) as compared to
other antidepressants and more importantly is effective in pa-
tients resistant to SSRI therapy (Woo et al. 2013). In addition,
this drug improves learning and increases long-term memory
in rodents, exerts a vigilance-enhancing effect in laboratory
animals and improves cognitive functions in depressed pa-
tients (Klasik et al. 2011; Jaffard et al. 1991; Zoladz et al.
2008). Tianeptine promotes neuroplasticity by increasing the
expression of genes of neuroplasticity factors (Reagan et al.
* Małgorzata Szafarz
malgorzata.szafarz@uj.edu.pl
1 Department of Pharmacokinetics and Physical Pharmacy, Faculty of
Pharmacy, Jagiellonian University Medical College, Krakow, Poland
2 Department of Animal Physiology, Institute of Biology and
Biochemistry, Faculty of Biology and Biotechnology, Maria
Curie-Sklodowska University, Lublin, Poland
Naunyn-Schmiedeberg's Archives of Pharmacology (2018) 391:185–196
https://doi.org/10.1007/s00210-017-1448-2
2007; Wlaź et al. 2011; Kuipers et al. 2013), reverses synaptic
plasticity, dendritic atrophy, memory impairment, and neuro-
nal loss under conditions of stress (Zhang et al. 2013).
Moreover, it has also additional properties, including neuro-
protection (Jantas et al. 2014), anticonvulsant activity
(Ceyhan et al. 2005; Ceyhan et al. 2007), antinociceptive ef-
fect (Uzbay et al. 1999), inhibitory effects on ethanol with-
drawal syndrome in rats (Uzbay et al. 2006), and anti-
inflammatory effect in lipopolysaccharide-stimulated microg-
lia (Slusarczyk et al. 2016). Recently, it has been revealed that
tianeptine is a μ-opioid receptor (MOR) agonist and the hy-
pothesis has been presented that precisely the MOR activation
is the initial molecular event responsible for modulation of the
glutamatergic system and for triggering many of known acute
and chronic effects of tianeptine, including its antidepressant/
anxiety actions (Gassaway et al. 2014).
Tianeptine is generally well tolerated by patients and
causes less side effects compared with SSRI and TCAs
(McEwen et al. 2010). In clinical trials, the most common
adverse effects caused by this drug were gastrointestinal (nau-
sea, constipation, abdominal pain) or CNS (headache, dizzi-
ness, change in dreaming) disturbances, which decreased in
frequency with continued treatment. Tianeptine appears to
have a lower propensity to cause sedative, anticholinergic,
and cardiovascular effects than classical TCAs and it has only
rarely been associated with hepatoxicity. The low incidences
of anticholinergic effects, sedation, and cardiotoxicity make
tianeptine particularly attractive for use in the elderly and in
patients with previous alcoholism who are known to have
increased sensitivity to the adverse effects of psychotropic
drugs. Tianeptine has a wide therapeutic margin, and usually,
overdosage has been associated with only minor transient ad-
verse effects (Wilde and Benfield 1995; Wagstaff et al. 2001).
However, a fatal case involving this drug has also been report-
ed (Proenca et al. 2007).
Unlike other antidepressants, tianeptine is not primarily
metabolized by the cytochrome P450 system. Instead, β-
oxidation is the main metabolic pathway. Two major metabo-
lites MC5 and MC3 are found in plasma and urine, respec-
tively, and the behavioral effects of MC5 are comparable to
those of tianeptine (Couet et al. 1990; Royer et al. 1988;
Samuels et al. 2017) (Fig. 1).
In preclinical studies, tianeptine exerted beneficial effects in
a number of behavioral models related to depression and anx-
iety in which rats and mice were used interchangeably. In phar-
macological experiments in which rats were used as an animal
model, this drug was administered either intravenously (i.v.) at
the doses of 2.5, 5, 10, and 20 mg/kg (Bilge et al. 2012) or
intraperitoneally (i.p.) at the doses of 2 and 10 mg/kg (Cavalla
et al. 2015); 5, 10, and 15 mg/kg (Della et al. 2012); or at
multiple (once a day for 21 days) doses of 10 mg/kg (Kuipers
et al. 2013; Glombik et al. 2016). Identification of new molec-
ular targets for tianeptine as well as the discovery
that metabolite MC5 plays an active role in the behavioral
effects of this drug provide a new perspective for interpreting
tianeptine clinical and preclinical data. However, interpretation
of pharmacological data might be difficult without the exten-
sive knowledge about pharmacokinetic (PK) profiles of both
tianeptine and MC5 following different routes of administra-
tion in laboratory animals commonly used in pharmacological
experiments. Up to date, there is only a limited information on
this subject in the available literature. Little is also known about
the hepatic clearance and hepatic metabolic ratio of this drug in
rodents. Tianeptine has been on the market for several decades
and despite the fact that for most antidepressants therapeutic
drug monitoring (TDM) has been recommended, there are no
reports concerning the application of TDM for tianeptine in the
clinic or the data dealing with tianeptine concentration-effect
relationship in depressed patients. However, taking into ac-
count the recent reports regarding its newmechanisms of action
and the contribution of metabolite MC5 to the observed phar-
macological response after its administration, the availability of
a fast and reliable analytical method for simultaneous determi-
nation of both compounds seems to be desirable not only from
the therapeutic point of view but also due to tianeptine potential
for the development of use disorder including abuse and addic-
tion (Bence et al. 2016; Gupta et al. 2017).
Therefore, the purpose of this study was to determine
PK of tianeptine and its active metabolite MC5 after two
different routes of administration of the parent drug to
rats, as well as its hepatic clearance, MC5 metabolic ratio,
and bioavailability. To achieve these goals a simple, fast,
and reliable analytical method for the simultaneous deter-
mination of tianeptine and MC5 metabolite in rats plasma
and liver perfusate using small sample volumes was de-
veloped and validated.
Experimental
Chemicals and materials
Tianeptine sodium salt (purity ≥ 95%) was obtained from
Cayman Chemical Company (USA), tianeptine metabolite
MC5 sodium salt (purity ≥ 95%) was obtained from Toronto
Research Chemicals (Canada). HPLC grade acetonitrile,
formic acid, and ammonium formate were purchased from
Merck (Germany) or Sigma Aldrich (USA). Pentoxifylline
used as an internal standard was obtained from Sigma
Aldrich (USA). Water was purified and deionized (conductiv-
ity below 0.1 μS) by the ultrapure water system HLP Smart
2000 (HydroLab, Poland). Chemicals used for the Krebs
Hanseleit buffer preparation, as well as sodium taurocholate
and glucose, were purchased from Sigma Aldrich (USA).
Control plasma, containing heparin as an anticoagulant,
was obtained from adult male Wistar rats (Animal Facility of
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the Jagiellonian University Medical College, Krakow,
Poland).
Animals
Male Wistar rats, 13–15 weeks of age and weighing between
200 and 220 g, were used in all the experiments. They were
kept under conditions of constant temperature (21–25 °C) and
a relative humidity of approximately 40–65% with a standard
light/dark cycle. Animals were housed in the stainless steel
cages with suspended wire-mesh floors and had free access
to water and the commercial rodent chow.
Pharmacokinetic study in rats
Six rats were used in PK experiments, and 3 days prior to the
experiment, rat jugular vein was cannulated allowing for the
multiple blood sampling from a single animal. The experi-
mental groups consisted of three rats each, and tianeptine dis-
solved in 0.9% sterile isotonic saline was administered i.v. at a
dose of 1 mg/kg or i.p. at the dose of 10mg/kg. Blood samples
(approximately 300 μL) were collected to Eppendorf tubes
containing heparin at 5, 15, 30, 60, 120, 240 and 480 min after
dosing. Plasma was harvested by centrifuging at 3000 r.p.m.
for 10 min and stored at − 30°C until bioanalysis. Plasma
samples (100 μL) were further processed as described in
BSample preparation^ section.
Liver perfusion study
Rat livers were perfused in situ using PS-1 perfusion system
from Harvard Apparatus-Hugo Sachs Electronics (HA-HSE).
Rats were anesthetized by an intraperitoneal injection of
ketamine/xylazine and after laparotomya ligature was placed
around the vena cava inferior above a left renal vein. Heparin
(ca. 500 units) was injected into the abdominal vena cava
inferior and the portal vein was cannulated. Then, the abdom-
inal vena cava inferior was transected and the perfusion buffer
was pumped into the portal vein. In the next step, the chest
was opened and a second cannulae was inserted through the
right atrium into the thoracic vena cava inferior. Finally,
the ligature around the abdominal vena cava inferior was
tightened. The perfusions were conducted using freshly pre-
pared Krebs Hanseleit buffer (118 mM NaCl, 4.7 mM KCl,
2.5 mM CaCl2, 1.19 mM KH2PO4, 1.18 MgSO4, and 25 mM
NaHCO3, oxygenated with 95% O2/5% CO2, pH 7.4) with an
addition of 1.2 g/L of glucose pumped through the liver at the
constant flow rate equal 20–25 mL/min using a peristaltic
pump. The temperature of the perfusion medium was thermo-
statically controlled at 37 °C. In each experiment, the common
bile duct was cannulated with PE-10 tubing. After an initial
stabilization period, within the first 15 min of perfusion,
tianeptine was added (300 μg) into the buffer along with the
100 μL (20 mg/mL) of sodium taurocholate. Experiments
were carried out in a recirculating manner with the total vol-
ume of perfusate equal 200mL. The flow rate was sufficient to
maintain the viability of the liver during the experiments, as
determined by the macroscopic appearance, bile flow and in
line measurement of oxygen consumption. Samples of bile
were collected in pre-weighed Eppendorf vials and measured
by gravimetric volume at the end of perfusion period, assum-
ing a density of 1. Perfusate was collected from the reservoir at
5 min intervals up to 45 min. To test the stability of tianeptine
under perfusion conditions, control experiments were per-
formed with application of the same solution to the perfusion
model without a liver resulting in no detectable degradation
products of tianeptine.
Preparation of stock solutions, calibration,
and quality control samples
Two stock solutions of each tianeptine and MC5 metabolite
were prepared separately by dissolving the reference com-
pounds in methanol to give a final concentration of 1.0 mg/
mL. They were further mixed and serially diluted with meth-
anol in order to produce an appropriate calibration and quality
control (QC) standards. The stock solution of pentoxifylline
(internal standard, IS) was prepared at 1.0 mg/mL in the mix-
ture of acetonitrile and water (50/50, v/v). Then IS working
solution was prepared by diluting the stock solution with ace-
tonitrile to give a concentration of 2.5 μg/mL. All stock and
working solutions were stored at + 4 °C.
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Calibration and QC samples were prepared by spiking
90 μL of pooled blank plasma or perfusate with a 10 μL of
a working solution to produce the calibration curve points
equivalent to 2000, 1000, 500, 250, 100, 50, 25, 10, and
1 ng/mL and QC standards at different concentrations along
the calibration range (LLOQ at 1 ng/mL, low at 3 ng/mL,
medium at 800 ng/mL, and high at 1800 ng/mL).
Sample preparation
Samples were prepared using protein precipitation with ace-
tonitrile. A portion (200 μL) of the working IS solution was
spiked to 100 μL of plasma or perfusate sample and vortex-
mixed for 90 s. Afterward, samples were centrifuged at 15000
r.p.m. for 5 min and the supernatant (100 μL) was transferred
to the autosampler vials.
LC-MS/MS quantification of tianeptine and its
metabolite MC5 in biological samples
An Agilent 1100 system (Agilent Technologies, Germany)
was used for solvent and sample delivery and chromatograph-
ic separation was achieved on an Aquasil C18 5 μm 3 ×
100 mm analytical column (Thermo Scientific, USA). The
mobile phase consisted of acetonitrile with an addition of
0.1% of formic acid (solvent A) and water with an addition
of 4 mMof ammonium formate (solvent B). Themobile phase
composition was 9:1 (A:B, v/v) and each LC-MS/MS run took
7 min. The flow rate was maintained at 400 μL/min and a
sample volume of 5 μL was injected into the LC-MS/MS
system.
Mass spectrometric detection was performed on an Applied
Biosystems MDS Sciex (Concord, Canada) API 2000 triple
quadrupole mass spectrometer with an electrospray ionization
(ESI) in the positive ion mode. The tandem mass spectrometer
was operated in the selected reaction monitoring (SRM) mode,
and Q1 and Q3 quadrupoles were set at unit mass resolution.
The ion source temperature was maintained at 450°C and the
ionspray voltage was set at 5500 V. The mass transitions of the
precursor/product ions were monitored at 437→ 292 m/z and
437→ 228 m/z for tianeptine, at 409→ 292 m/z and 409→
228 m/z for metabolite MC5, and at 279→ 181 m/z for the IS.
The Applied Biosystems Analyst version 1.4.2 software was
used to control the LC-ESI/MS/MS system and to collect and
treat the data.
Method validation
Since perfusate is a simple matrix with strictly defined and
fixed composition, the full method validation according to
the EMA guidelines was performed only for the quantification
of tianeptine and its MC5 metabolite in rat plasma (EMA
2012).
Precision and accuracy of the assay were assessed by
performing replicate (n = 5) analyses of QC samples at differ-
ent concentration levels on the same day (within-day) and on
three different days (between-days). Accuracy (percent of re-
covery) was evaluated, using the following formula: [mean
back calculated concentration/theoretical concentration] ×
100. Precision was expressed as a percent relative standard
deviation (RSD, CV%). The LLOQ based on QC samples
was defined as the lowest analyte concentration that can be
measured with the RSD ≤ 20% and the accuracy of 100 ± 20%
on a day-to-day basis.
As the concentrations in selected samples were over
2000 ng/mL, the QC samples at fivefold of the highest level
of calibration standard concentration were diluted by 10-fold
and the dilution integrity was investigated by comparing the
calculated concentration with nominal value.
An assessment of matrix effect (ME) was done by compar-
ing the peak areas of analytes in extracted samples of blank
plasma spiked with an analyzed compounds (post-extraction
addition) with the corresponding peak areas obtained by in-
jection of standard solutions at the appropriate concentration.
For evaluation of the relative matrix effect, five different
sources of rat plasmawere used. Process efficiency (combined
absolute matrix effect and recovery) was evaluated at three
replicates of each QC samples. It was determined by compar-
ing peak area obtained from extracted plasma samples with
the standard solutions at the appropriate concentrations
(Matuszewski et al. 2003).
The stability of analytes was determined in the battery of
tests according to the appropriate guidelines. Namely, the
bench top stability (for 2 h), freezer stability (at − 30°C for
90 days), freeze/thaw stability and post preparative
autosampler stability (at 10°C up to 24 h). Samples were con-
sidered to be stable when 85–115% of the initial concentra-
tions were found.
Additionally, the stability of standard working solutions
was assessed after 90 days of storage at + 4°C.
Pharmacokinetic analysis
Pharmacokinetic parameters were calculated by employing a
non-compartmental approach, using PhoenixWinNonlin soft-
ware v. 6.3 (Pharsight, USA). For i.v. administration, plasma
concentration at time zero (C0) was back-extrapolated using
log-linear regression, while the maximum concentration after
i.p. administration (Cmax) and the time to Cmax (tmax) were
obtained directly from the concentration-time data. The area
under the mean plasma concentration versus time curve ex-
trapolated to infinity (AUC0-inf) was estimated using the log/
linear trapezoidal rule. AUMC0-inf was estimated by calcula-
tion of the total area under the first-moment curve by combin-
ing the trapezoid calculation of AUMC0-t and extrapolated
area. The mean residence time (MRT) was calculated from
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AUMC0-inf/AUC0-inf. The terminal rate constant (λz) was cal-
culated by log-linear regression of the drug concentration data
in the terminal phase and the terminal half-life (t1/2) was cal-
culated as 0.693/λz. The systemic clearance (CL) was estimat-
ed from the administered dose divided by AUC0-inf. The vol-
ume of distribution at steady state (Vss) was calculated from
Di.v.⋅AUMC/AUC2, whereDi.v is the dose administered i.v. in
mg per kg of body weight. The concentration versus time
profiles of the parent drug and metabolite following both
routes of administration were also fitted simultaneously to
the pharmacokinetic model with a metabolite compartment
to obtain one set of parameters. During iteration process, the
fraction of dose absorbed (F) was fixed to the value calculated
using the following equation:
F ¼ AUC0−t i:p:ð Þ∙Di:v:
AUC0−t i:v:ð Þ∙Di:p:
ð1Þ
where AUC0-t is the area under the concentration versus
time curve calculated to the last measured point and D is the
dose administered.
Non-compartmental estimates of hepatic pharmacokinetic
parameters were determined from the outflow concentration-
time profiles. The hepatic extraction ratio (ERH) was
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Fig. 2 Product ion mass spectra
of [M +H+]+ ions of tianeptine
(a), metabolite MC5 (b), and IS
(c) with the proposed
fragmentation paths
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calculated according to the following equation:
ERH ¼ CLHQ ð2Þ
where CLH is a hepatic clearance (per gram of liver) andQ is a
perfusate flow (per gram of liver).
The apparent hepatobiliary clearance (CLb,app) was cal-
culated as the cumulative amount of drug excreted in bile
divided by the AUC0-t of the drug in the perfusate. The
metabolic ratio of MC5 metabolite was calculated by di-
viding the AUC0-t of the metabolite by that of tianeptine.
Fig. 3 Representative
chromatogram of QC sample at
the LLOQ concentration (1 ng/
mL). a Tianeptine. b Metabolite
MC5. c Internal standard. dBlank
sample
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Statistical analysis
Statistical analysis was performed using Excel 2010
(Microsoft) and Statistica 10 (StatSoft, Tulsa, OK). Results
were expressed as geometric means and 90% confidence in-
tervals (CI) or arithmetic means ± SD.
Results and discussion
Analytical method and its validation
In order to avoid a time-consuming and tedious liquid–liquid
extraction procedure, a simple and rapid one-step protein pre-
cipitation method was developed with acetonitrile selected as
the optimal precipitation agent. Electrospray ionization oper-
ated in the positive ion mode was used for the LC-MS/MS
analysis to provide the best sensitivity and selectivity. For the
analyzed compounds the dominant ions in the Q1 spectra were
used as the precursor ions to obtain Q3 product ion spectra.
The resulting SRM transitions (precursor ion m/z→ product
ion m/z) for each analyte were as follows: 437→ 292 and
437→ 228 for tianeptine, 409→ 292 and 409→ 228 for
MC5, and 279→ 181 for the IS. The first pair of ions was
used as a quantifier and the second for the identification pur-
pose (qualifier). Product ion mass spectra of [M +H]+ ions of
tianeptine, metabolite MC5, and IS with the proposed frag-
mentation paths are presented in Fig. 2. An Aquasil C18 (3 ×
100 mm, 5 μm) analytical column gave the best retention and
baseline separation which in the case of tianeptine and MC5
metabolite was highly desirable to prevent the possibility of
peak area contribution from one to the other since for the both
analytes the most abundant product ion was at 292 m/z. A
mobile phase consisting of acetonitrile with formic acid and
water with ammonium formate was used at isocratic condi-
tions. The representative extracted ion chromatograms (XIC)
of a quality control sample at the concentration of 1 ng/mL
(LLOQ) extracted from the supplemented plasma as well as a
blank sample are shown in Fig. 3.
The specificity of the method was evaluated by analyzing
blank plasma samples from six rats with no interfering peaks
observed. The calibration curves were linear over the concen-
tration range from 1 up to 2000 ng/mL of both analytes with
correlation coefficients above 0.99 and consistent slope values
when evaluated by weighted (1/x2) least squares linear regres-
sion. The back calculated concentrations of calibrators are
presented in Table 1. The lowest concentration on the calibra-
tion curve was chosen based on the expected concentrations in
Table 1 Back-calculated plasma
concentrations of calibrators for
tianeptine and metabolite MC5
(n = 5)
Nominal
concentration
(ng/mL)
Tianeptine MC5
Back-calculated
concentration (mean
± SD)
RSD
(%)
Accuracy
(%)
Back-calculated
concentration (mean
± SD)
RSD
(%)
Accuracy
(%)
1 1.00 ± 0.002 0.22 99.83 1.00 ± 0.002 0.19 99.90
10 10.41 ± 1.00 9.7 104.14 10.34 ± 0.55 5.36 103.44
25 25.48 ± 2.05 8.03 101.92 24.93 ± 0.86 3.47 99.73
50 53.48 ± 2.57 4.80 106.96 53.68 ± 2.79 5.19 107.36
100 101.03 ± 8.94 8.85 101.03 99.30 ± 13.78 13.87 99.30
250 242.49 ± 12.44 5.13 96.99 238.45 ± 22.96 9.63 95.38
500 475.32 ± 31.17 6.56 95.06 473.80 ± 60.43 12.75 94.76
1000 1005.03 ± 15.62 1.55 100.50 1082.34 ± 51.35 4.74 108.23
2000 1967.83 ± 91.36 4.64 98.39 1912.68 ± 124.95 6.53 95.63
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Table 2 Within-day and between-days accuracy (% of nominal concentration) and precision (%RSD) of tianeptine and MC5 in rat plasma (n = 5)
QC nominal concentration
(ng/mL)
Tianeptine MC5
Intra-day (%) Inter-day (%) Intra-day (%) Inter-day (%)
Accuracy Precision Accuracy Precision Accuracy Precision Accuracy Precision
1 99.78 10.8 100.19 8.03 89.67 0.23 100.96 11.49
3 107.29 3.34 105.48 5.12 91.97 2.84 98.11 8.15
800 100.25 9.54 96.63 8.96 90.48 3.69 93.10 7.59
1800 102.79 6.15 101.28 6.61 97.71 11.77 100.89 9.56
the biological matrices and the lower limit of quantification
(LLOQ) was established at 1 ng/mL. LLOQ was accepted
with a relative standard deviation of less than 20% and signal
to noise ratio at least 20:1 (see Fig. 3). As seen in Table 2 the
precision and accuracy values were within the acceptance
criteria established by EMA for bioanalytical methods valida-
tion (EMA 2012).
The relative ME was expressed as RSD (%) and the results
showed a good repeatability from the samples coming from
the pooled plasma as well as those coming from different
animals and CV values were below 15%. The analysis of
absolute ME did not show significant changes in ionization
and the absolute recovery (process efficiency) was on average
60% for both analytes across the concentration range.
The stability of tianeptine and metabolite MC5 in rat plas-
ma was investigated under a variety of storage and process
conditions as described in BMethod validation^ section, and
there were no stability related problems during the routine
analysis of samples from pharmacokinetic studies.
Pharmacokinetic study
Pharmacokinetic parameters, calculated based on the
concentration-time profiles obtained after a single i.v. or i.p.
administration of tianeptine, are presented in Table 3.
Regardless of the route of administration, the elimination of
MC5 metabolite was much slower than that of the parent drug
with the mean terminal half-life for the MC5 metabolite equal
7.53 h as compared to 1.16 h for tianeptine. These results are
in accordance with the outcomes of previously performed
studies in rats and humans (Couet et al. 1990; Royer et al.
1988). After i.p. administration, tianeptine reached the peak
concentration (Cmax) at the first sampling time (5 min), while
Cp
Vc
 (1-fm)∙ke
Ct
Vt
k21  k12 
      Di.v.
 fm∙ke  keM 
    F∙Di.p.
CM 
Vm
Fig. 4 Pharmacokinetic model of tianeptine and its metabolite MC5 after
two routes of administration of the parent drug. (F is fraction absorbed,
Vc, Vm, and Vt are volumes of the central, metabolite, and tissue
compartments, respectively, k12 and k21 are first order distribution and
redistribution rate constants, ke and keM are the first order rate constants
for elimination of the parent drug and metabolite, respectively, and fm is
the fraction of the dose metabolized
192 Naunyn-Schmiedeberg's Arch Pharmacol (2018) 391:185–196
Table 3 Serum pharmacokinetic parameters calculated from concentration vs. time data (n = 3) of tianeptine and MC5 metabolite determined by non-
compartmental analysis after a single intravenous or intraperitoneal administration of tianeptine to rats at a dose of 1 or 10 mg/kg, respectively. Data are
presented as geometric mean (GM), 90% confidence interval (CI), and coefficient of variation (CV)
Parameter Intravenous 1 mg/kg Intraperitoneal 10 mg/kg
Tianeptine MC5 Tianeptine MC5
GM
(90% CI)
CV% GM
(90% CI)
CV% GM
(90% CI)
CV% GM
(90% CI)
CV%
Co/Cmax (mg/L) 1.27
(0.86–1.9)
23.64 0.117
(0.064–0.212)
22.16 6.65
(6.44–6.87)
1.3 2.02
(1.1–3.43)
22.35
tmax (h) n/a 0.4
(0.054–2.89)
86.6 0.083 0 0.5 0
λz (h
−1) 0.59
(0.25–1.42)
41.7 0.09
(0.085–0.099)
3.05 0.475
(0.332–0.68)
14.73 0.187
(0.07–0.498)
34.48
t0.5λz (h) 1.16
(0.49–2.75)
64.34 7.53
(6.98–8.13)
3.05 1.46
(1.018–2.085)
14.03 3.69
(1.39–9.83)
42.29
Vz(Vz/F) (L/kg) 2.41
(0.91–6.4)
40.25 n/a 12.42 6.51
(4.03–10.53)
18.15 n/a 48.03
AUC0-inf (mg∙h/L) 1954.02
(1411.02–2705.94)
19.44 2371.56
(1617.78–3476.46)
15.17 11,621.28
(9737.58–13,869.36)
7.05 14,415.96
(12,323.88–16,863.24)
6.35
CL/(CL/F) (L/h/kg) 1.84
(1.33–2.55)
21.39 n/a 15.52 3.1
(2.59–3.69)
7.17 n/a 5.98
Vss (L/kg) 2.03
(0.89–4.62)
55.64 n/a n/a n/a
MRT (h) 1.25
(0.66–2.36)
32.64 8.28
(6.53–10.5)
9.51 0.66
(0.51–0.87)
10.36 4.1
(1.83–9.24)
34.52
metabolite MC5 attained Cmax at 30 min after both routes of
administration which is faster than the time reported in
humans (2.96 ± 0.95 h) (Carlhant et al. 1990). Moreover, in
contrast to the studies performed in humans, where the plasma
metabolite concentrations were lower than those of the parent
drug, in rats, the concentrations of MC5 after initial 30 min
were similar or higher than those of tianeptine and an overall
exposure to MC5 was 1.2 times higher as quantified by AUC
than that of tianeptine regardless of the route of administration.
In mice, which are the most commonly used animal model in
behavioral studies, the conversion of tianeptine to MC5 metab-
olite seems to be even more efficient than in rats (Samuels et al.
2017; own unpublished data). Thus, in the light of recent re-
ports regarding the pharmacological activity of metabolite
MC5 being equal to that of the parent drug, the results of
behavioral experiments performed on mice might be mislead-
ing (Samuels et al. 2017). Considering that the pharmacokinetic
profile of tianeptine and its active metabolite in rats seems to be
more in agreement with the results reported in humans as com-
pared to the profile observed in mice it appears reasonable to
argue that in this particular case rats could be better animal
model than mice to be used in the further studies of tianeptine.
To facilitate the dosage selection for the prospective
pharmacological experiments, the concentration versus
time data of the parent drug and metabolite following
both routes of administration were fitted simultaneously
to the two-compartment pharmacokinetic model with an
additional metabolite compartment (Fig. 4). The measured
and pharmacokinetic model predicted concentration ver-
sus time profiles of tianeptine and its metabolite MC5
following i.v. or i.p. administration of the parent drug at
the doses of 1 and 10 mg/kg, respectively, are presented
in Fig. 5. It can be seen that the model very well captured
the measured concentrations, what may be additionally
confirmed by the low values of coefficients of variation
(Table 4). Calculated based on the values of elimination
rate constants, biological half-lives of tianeptine and MC5
metabolite were 0.25 and 1.66 h, respectively.
The absolute bioavailability of tianeptine after intraperito-
neal administration to rats calculated according to Eq. 1
equaled 69.4%. After i.p. administration, the first-pass effect
was supposed to be less pronounced as compared to the oral
route therefore these results once again confirm that in rats,
metabolism of tianeptine is more efficient than in man where
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Fig. 5 Measured (symbols) and pharmacokinetic model predicted (lines)
concentration versus time profiles of tianeptine and its metabolite MC5
following intravenous (a) and intraperitoneal (b) administration of the
parent drug to rats at the doses of 1 and 10 mg/kg, respectively
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Fig. 6 The perfusate concentration-time profile of tianeptine in the iso-
lated perfused rat liver (mean ± SD; n = 3) after a single dose administra-
tion of the drug (300 μg)
Table4 Pharmacokinetic
parameters of tianeptine
and its metabolite MC5
following intravenous
and intraperitoneal
administration to rats
estimated using the PK
model with a metabolite
compartment presented
in Fig. 3
Parameter Estimate CV (%)
VC (L/kg) 0.761 24.62
Vm/fm (L/kg) 2.971 15.6
ke (h
−1) 2.792 16.11
keM (h
−1) 0.416 12.99
k12 (h
−1) 0.504 39.92
k21 (h
−1) 0.628 18.62
F 0.694 fixed
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according to the available data, tianeptine is almost complete-
ly absorbed after oral administration (Royer et al. 1988; Wilde
and Benfield 1995).
Since liver is considered to be the main metabolic site for
tianeptine, an additional experiments were performed using
the system for isolated perfused organs of small animals in
order to determine the hepatic clearance and hepatic metabolic
ratio of this drug in rats. For the isolated rat liver perfusion
(IPRL) studies, the total amount of drug added to the perfusion
buffer equaled 300 μg, which considering the volume of the
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buffer used in each experiment (200 mL) gave the concentra-
tion of 1500 ng/mL. A similar C0 was reached after i.v. ad-
ministration of tianeptine at the dose of 1 mg/kg (Table 3). The
concentration of tianeptine in the perfusion buffer declined
quite fast from the average value of 952 ng/mL at the first
sampling time (5 min) to 17 ng/mL after 45 min (Fig. 6).
The observed hepatic clearance was high and on average
equal to the perfusion buffer flow rate. According to Eq. 2, it
gave the high value of ERH (104.55 ± 16.99%) further indi-
cating that tianeptine in rats undergoes an extensive hepatic
first-pass metabolism. In contrast to these findings, it has been
reported that in humans, tianeptine is not subject to first-pass
hepatic metabolism and its oral bioavailability equals to al-
most 100% (Wilde and Benfield 1995). The main tianeptine
metabolites reported in the literature are MC5 (pentanoic acid
derivative) and MC3 (propionic acid derivative) both being
the products of β-oxidation. However unexpectedly, in the
IPRL experiments, despite the high ERH, the metabolic ratio
of MC5 was quite low (18.76 ± 8.11%) and the percent of
MC5 eliminated into the bile up to 45 min of perfusion was
only 3.07 ± 0.66% of the administered dose. At the same time
the apparent hepatobiliary clearance was also low (0.2 ±
0.09 mL/min). Additionally, the percent of unchanged drug
eliminated into the bile up to 45 min of perfusion was only
0.94 ± 0.33% of the administered dose. SinceMC3metabolite
was undetected (based on the theoretical mass/charge ratio) in
all analyzed samples, further analysis was performed in search
of possible different routes of tianeptine metabolism in rats.
Assuming that tianeptine, as well as its metabolites should
give the same fragment ion m/z 292, the Q1 scans of rat bile
were performed in the precursor ion mode. The major metab-
olites found in the analyzed samples are presented in Fig. 7.
Beside previously identified MC3 and MC5 metabolites, dif-
ferent conjugates, mainly with glutamine and glucuronic acid,
were also present what may explain the high ERH value and
the low metabolic ratio of MC5 observed in rats in the liver
perfusion experiments.
Conclusions
In this manuscript, pharmacokinetics of tianeptine and its ac-
tive metabolite MC5 in rats following two routes of adminis-
tration was studied. In order to achieve study goals, a sensitive
and selective high performance liquid chromatography-
tandemmass spectrometry method for the simultaneous deter-
mination of both compounds was developed. The validation
of the method showed that the method is accurate and precise
with the linear response of mass spectrometer in the plasma
concentration range from 1 to 2000 ng/mL. This method may
also be used in human studies as the transfer of an analytical
method to a similar matrix, e.g., from rat to human plasmawill
require only part ial val idat ion. Pharmacokinet ic
analysis indicated that in rats, elimination of MC5 metabolite
was much slower than that of the parent drug. In contrast to the
results of the studies performed in humans, in the elimination
phase, concentrations of MC5 were higher than those of
tianeptine, although these differences are less pronounced
when comparing MC5 concentrations in mice and humans.
The results of ex vivo study indicated that in rats both MC5
metabolite and the parent drug are eliminated as glutamine
and glucuronide conjugates. The proposed in this study phar-
macokinetic model describing the concentration-time profiles
of tianeptine and MC5 metabolite after two routes of admin-
istration may facilitate the dosage selection for the prospective
pharmacological experiments.
In view of recent reports demonstrating the activity ofMC5
metabolite being equal to that of tianeptine itself, the differ-
ences in the pharmacokinetics of these two compounds ob-
served especially in the metabolism process between labora-
tory animals and man seem particularly important for the ac-
curate interpretation of the results of pharmacological
experiments.
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